3 withdrawn, 1 active not recruiting. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Withdrawn 2, Active not recruiting 1 |
| Phase 1 | 1 | Withdrawn 1 |
Follow foralumab: new trials by email Literature Review of foralumab trials Research Report on foralumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients Foralumab, Placebo - Secondary Progressive Multiple Sclerosis | Phase 2 | Active not recruiting | Tiziana Life Sciences LTD | 54 | 2023-11-15 | 2026-07-02 |
| A Study of Oral Foralumab in Participants With Moderate to Severely Active Crohn's Disease Foralumab - Crohn's Disease | Phase 1 | Withdrawn | Tiziana Life Sciences LTD | 2022-05-01 | 2022-10-20 | |
| In-patient COVID-19 Study of Intranasal Foralumab Foralumab, Placebo - Covid19, COVID-19 Lower Respiratory Infection | Phase 2 | Withdrawn | Tiziana Life Sciences LTD | 2022-04-30 | 2022-10-19 | |
| Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DM Foralumab, placebo, Omeprazole 20mg - NASH - Nonalcoholic Steatohepatitis, NAFLD | Phase 2 | Withdrawn | Tiziana Life Sciences LTD | 2017-12-01 | 2019-09-12 |
COVID-19 (1) · Crohn Disease (1) · Diabetes Mellitus, Type 2 (1) · Inflammatory Bowel Diseases (1) · Multiple Sclerosis, Chronic Progressive (1) · Non-alcoholic Fatty Liver Disease (1)
United States (1)